Company intelligence / Profile preview

Cognivue

Victor, New York, United Statescognivue.com ↗

Ownership: Private
Employees: ~45
Development stage: Commercial

Overview

The company has developed the first FDA-cleared computerized test of cognitive function. Clinical studies show that its devices can distinguish amyloid-positive from amyloid-negative individuals and identify preclinical Alzheimer's disease with high sensitivity. Its tools are validated against gold-standard assessments like MoCA and SLUMS and are used to expand access to early detection of dementia risk in clinical practice and research trials.

Therapeutic areas: Neurology
Modalities: DeviceDigital cognitive assessment toolNon-pharmacological therapy
Industry: Digital Health Medical Devices

Partnerships

Global Alzheimer's Platform Foundation/Bio-Hermes study partners including Eli Lilly & Company, AbbVie, MerckMilken Institute Alliance to Improve Dementia Care members such as AARP and Biogen

Beyond the preview

Go deeper on Cognivue.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cognivue.

Explore the full profile